//
Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure
Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure
Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study
Baseline Features of the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) Trial
Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification
SGLT2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Trials
Nitrosative stress drives heart failure with preserved ejection fraction